Dudediligence.

Capricor Therapeutics, Inc

CAPRNASDAQ · Pharmaceutical Preparations
Write an idea

Insiders

Last 12 months

Sales planned on beside the trades reported on , and whether each names a .

Planned ·

$7,859,023

5 notices · 282,529 sh

Oct 2025 to Oct 2026

Reported ·

$6,877,940

9 sales · 0 buys

Oct 2025 to Jun 2026

The two figures cover different periods.

7 of 9 reported sales carry the 10b5-1 box. Together they are 0.38% of the shares on issue.

PLANNED · FORM 144Oct 2025 to Oct 2026REPORTED · FORM 4Oct 2025 to Jun 2026N2025DJ2026FMAMJJASO2026-05-19: Musket David B, Form 1442026-04-02: Karimah Es Sabar, Form 1442026-03-31: Karen Krasney, Form 1442026-03-31: ANTHONY BERGMANN, Form 1442026-03-31: Karimah Es Sabar, Form 1442026-03-31: Krasney Karen, sold2026-03-31: Bergmann Anthony, sold2026-03-31: Sabar Karimah Es, sold2026-04-02: Sabar Karimah Es, sold2026-05-01: Krasney Karen, sold2026-05-01: Bergmann Anthony, sold2026-06-22: Krasney Karen, sold2026-06-22: Bergmann Anthony, sold
under a ▼ salesize is dollars

Form 144 notices, newest first

2026-05-19Musket David B, Director$273,200
10,000 shplan 2026-05-18Form 4s on file end Jun 23144 ↗
2026-04-02Karimah Es Sabar, Director$226,773
7,529 shplan 2025-12-27144 ↗
Form 4, 2026-04-03: sold 7,529 at $32.00 Form 4 ↗
2026-03-31Karen Krasney, EVP, GENERAL COUNSEL$2,082,750
75,000 shplan 2025-12-30144 ↗
Form 4, 2026-04-01: sold 25,000 at $30.12 Form 4 ↗
2026-03-31ANTHONY BERGMANN, CHIEF FINANCIAL OFFICER$2,082,750
75,000 shplan 2025-12-30144 ↗
Form 4, 2026-04-01: sold 25,000 at $30.13 Form 4 ↗
2026-03-31Karimah Es Sabar, Director$3,193,550
115,000 shplan 2025-12-27144 ↗
Form 4, 2026-04-01: sold 115,000 at $30.57 Form 4 ↗